01 AI-Assisted Treatment Planning Is Improving Radiosurgery Precision The need for more accurate target identification and individualized treatment is increasing the use of AI in radiosurgery planning and outcome prediction. A 2026 systematic review of 21 studies found that AI models for brain metastases treated with stereotactic radiosurgery reported AUCs ranging from 0.70 to 0.98, with stronger results from models combining MRI-derived radiomics and clinical data. This transition can improve treatment planning, support risk stratification, and help clinicians identify patients who may require closer post-treatment monitoring.
02 MRI-Guided Radiosurgery Is Enabling Real-Time Treatment Adaptation The need to account for anatomical changes during multi-session treatment is increasing interest in MRI-guided radiosurgery and online adaptive workflows. A 2025 study of 26 intracranial cases demonstrated the feasibility of online adaptive fractionated stereotactic radiosurgery using a low-field MR-linear accelerator, with simulated end-to-end validation showing a less than 2.5% difference between measured and planned target dose. This shift can improve target coverage and normal-brain sparing while allowing treatment plans to respond more precisely to changes during therapy.
01 Cancer Center Expansion and Rising Brain and Spinal Tumor Cases Increase Radiosurgery Demand and Drive Market Growth. Expansion of cancer treatment centers increases demand for advanced radiation equipment as hospitals add capacity for specialized oncology services. Greater availability of radiotherapy infrastructure creates additional requirements for radiosurgery systems, treatment platforms, and supporting equipment. The outcome is higher procurement demand from hospitals and oncology centers seeking to expand treatment capacity. For example, national cancer programs such as Tanzania’s expansion of cancer centers have included increased access to radiotherapy services and related oncology infrastructure.The burden of brain and central nervous system tumors creates continued demand for treatment options that can address tumors in sensitive anatomical locations. This patient need supports the use of radiosurgery systems for selected brain and spinal tumors where highly focused radiation can be clinically appropriate. The outcome is greater demand for specialized radiosurgery equipment and treatment services at oncology facilities. IARC reported 321,731 new brain and CNS cancer cases globally in 2022, illustrating the patient population requiring specialized cancer care.
01 High Cost of Radiosurgery Systems and Treatment and Limited Access to Advanced Radiosurgery Facilities Restrain Market Expansion High costs of radiosurgery systems and treatment can limit adoption among hospitals and patients, particularly where healthcare budgets are constrained. Advanced equipment, installation, maintenance, treatment planning, and specialized clinical services increase the overall cost of radiosurgery. These financial barriers can delay equipment purchases, restrict patient access, and slow market expansion.Limited access to advanced radiosurgery facilities can restrict the availability of specialized treatment, particularly in rural and underserved regions. High infrastructure requirements, limited treatment centers, and uneven distribution of advanced equipment can make patients dependent on distant specialized hospitals. These access gaps can reduce procedure volumes and limit the broader adoption of radiosurgery
01 Radiosurgery-Immunotherapy Integration and Outpatient Services Are Creating New Revenue Opportunities and Offers Growth Market Opportunities. Oncology hospitals, cancer centers, radiation specialists, and pharmaceutical companies can combine radiosurgery with immunotherapy for selected cancer treatment pathways. Combination protocols create revenue opportunities through treatment packages, clinical collaborations, and demand for advanced radiation systems. Companies such as Varian and Elekta operate in advanced radiation oncology technologies.Hospitals, ambulatory treatment centers, and radiation oncology providers can deliver selected radiosurgery procedures without prolonged inpatient stays. Outpatient models create revenue through higher treatment throughput, facility utilization, procedure-based payments, and related patient services. Companies such as Accuray provide radiosurgery systems that support outpatient treatment settings.
01 Shortage of Specialized Radiosurgery Professionals and Complex Treatment Planning for Multiple Tumors Hinder Market Growth. Radiosurgery requires radiation oncologists, medical physicists, dosimetrists, and trained technologists with specialized expertise. Workforce shortages and uneven distribution can limit treatment capacity, increase operational pressure, and make it difficult for providers to expand services. WHO continues to report persistent global health-workforce shortages and distribution gaps.Accurate radiosurgery planning becomes more difficult when patients have multiple lesions, large tumors, or rapidly changing tumor volumes. These cases require repeated imaging, careful dose optimization, and multidisciplinary decisions, increasing workflow complexity and limiting the number of patients that centers can efficiently treat.
May 2026 Accuray Incorporated and the University of Wisconsin School of Medicine and Public Health announced a 10-year strategic research collaboration to advance personalized cancer treatment using Accuray’s adaptive radiation therapy technologies. The collaboration focuses on clinical research, education, training, and development of adaptive treatment approaches that support precision radiation therapy applications.
January 2026 Elekta received U.S. FDA 510(k) clearance for its Elekta Gamma Knife radiosurgery system to treat patients with refractory, drug-resistant mesial temporal lobe epilepsy. The regulatory approval expanded the clinical applications of Elekta’s stereotactic radiosurgery platform beyond traditional intracranial tumor treatments.
September 2025 Accuray launched the Accuray Stellar™ Solution, an advanced radiotherapy solution based on the Radixact® Treatment Delivery System. The platform introduced adaptive radiotherapy capabilities designed to provide clinicians with enhanced treatment flexibility and precision for individualized cancer care.
September 2025 Elekta announced that its Leksell Gamma Knife radiosurgery platform reached the milestone of treating more than two million patients globally. The milestone highlighted the continued clinical adoption of Gamma Knife technology in stereotactic radiosurgery applications.